SULFONAMIDES DUPLEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SULFONAMIDES DUPLEX (SULFONAMIDES DUPLEX).
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
| Metabolism | Hepatic metabolism via N-acetylation and glucuronidation; CYP450 involvement is minimal. |
| Excretion | Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%. |
| Half-life | Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination. |
| Protein binding | 70-90% bound primarily to albumin, with variable binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.2 L/kg, indicating limited extravascular distribution; higher Vd in neonates and critically ill patients. |
| Bioavailability | Oral: 85-100% for short-acting sulfonamides; variable (50-80%) for sustained-release formulations. |
| Onset of Action | Oral: 1-2 hours (peak plasma concentration 2-6 hours); IV: immediate (within minutes). |
| Duration of Action | Oral: 6-12 hours (depends on formulation and renal function); sustained-release formulations may extend to 24 hours. |
| Molecular Weight | 250.27 |
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
| Dosage form | SUSPENSION |
| Renal impairment | CrCl 30-50 mL/min: 500 mg twice daily; CrCl 15-29 mL/min: 500 mg once daily; CrCl <15 mL/min: avoid use. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: 500 mg twice daily; Class C: avoid use. |
| Pediatric use | 2 months to 12 years: 20-30 mg/kg/day divided every 12 hours; maximum 1000 mg/day. |
| Geriatric use | Initial dose 500 mg twice daily; monitor renal function and adjust accordingly. |
| 1st trimester | Avoid; associated with congenital malformations (e.g., cardiovascular, neural tube defects) in first trimester exposure. Sulfonamides are generally contraindicated due to teratogenicity risk. |
| 2nd trimester | Use only if clearly needed; no large studies show major malformations, but risk of kernicterus in neonates if given near term; preferred alternatives exist. |
| 3rd trimester | Contraindicated; risk of kernicterus in newborns due to displacement of bilirubin from albumin; can cause hemolytic anemia in G6PD-deficient fetuses. |
Clinical note
Comprehensive clinical and safety monograph for SULFONAMIDES DUPLEX (SULFONAMIDES DUPLEX).
| Placental transfer | Readily crosses the placenta; fetal serum concentrations reach 50-90% of maternal levels. Competes with bilirubin for albumin binding sites, increasing risk of kernicterus. |
| Breastfeeding | Excreted into breast milk in low concentrations; potentially hazardous in infants with G6PD deficiency or hyperbilirubinemia. Generally avoided during breastfeeding; if used, monitor infant for jaundice, hemolysis, and rash. |
■ FDA Black Box Warning
Sulfonamides have been associated with fatal hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
| Serious Effects |
Hypersensitivity to sulfonamides or any component of the formulationInfants <2 months of age (except for congenital toxoplasmosis treatment)Breastfeeding infants with G6PD deficiency or hyperbilirubinemiaThird trimester of pregnancy (risk of kernicterus)Severe hepatic or renal impairmentPorphyria (may precipitate acute attack)
| Precautions | Hypersensitivity reactions, hematologic toxicity (e.g., agranulocytosis), photosensitivity, hepatic injury, renal impairment, and kernicterus in neonates. |
| Food/Dietary | Avoid alcohol; may cause disulfiram-like reaction. Avoid potassium-rich foods (e.g., bananas, oranges) if used with potassium-sparing diuretics as hyperkalemia risk. No significant food-drug interactions; take with food if GI upset occurs. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) – Avoid; risk of kernicterus and hemolytic anemia in nursing infants, especially those with G6PD deficiency, prematurity, or hyperbilirubinemia. |
| Teratogenic Risk | First trimester: Possible increased risk of neural tube defects and cardiovascular anomalies based on animal studies and limited human data. Second and third trimesters: Risk of kernicterus in neonates due to bilirubin displacement from albumin; avoid near term. Sulfonamides are generally avoided in pregnancy due to potential for hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient fetuses and maternal hypersensitivity. |
| Fetal Monitoring | Monitor maternal complete blood count, renal function, and liver function tests. Fetal ultrasound for anomaly assessment if used in first trimester. In late pregnancy, monitor neonatal bilirubin levels and signs of hemolysis or jaundice. Consider G6PD status in mother and family history before use. |
| Fertility Effects | No significant adverse effects on fertility reported in animal or human studies. Sulfonamides may cause reversible oligospermia in males with prolonged use, but overall impact on fertility is minimal. |
| Clinical Pearls | Sulfonamides duplex (e.g., sulfamethoxazole-trimethoprim) are bacteriostatic; ensure adequate hydration to prevent crystalluria. Monitor for hypersensitivity reactions (Stevens-Johnson syndrome). Avoid in G6PD deficiency. Potentiates warfarin, sulfonylureas, and phenytoin. Check renal function before dosing. |
| Patient Advice | Take with a full glass of water and stay well-hydrated throughout treatment. · Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur. · Complete full course even if symptoms improve to prevent resistance. · Report rash, fever, sore throat, or unusual bruising immediately. · Inform doctor if taking blood thinners, diabetes meds, or seizure meds. |